# Neurogastrx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurogastrx

- Industry: Pharmaceuticals
- Headquarters: Woburn, US
- Website: www.neurogastrx.com
- Total disclosed funding: $105M
- Latest round: Series B (Aug 26, 2021)
- Investors on record: 7

## About

Neurogastrx, Inc. is a US-based biopharmaceutical company dedicated to the discovery and advancement of therapies for gastrointestinal disorders that significantly affect the enteric nervous system.Founded in 2012 and headquartered in Woburn, US, Neurogastrx, Inc. specializes in developing innovative solutions for gastrointestinal conditions. The company has completed three funding rounds, with the most recent being a Series B round in August 2021, raising USD 60.00 mn led by Vivo Capital. Founders Cyril De Colle, Daniel Amoako, and Pankaj Pasricha have experience in the biopharmaceutical field, contributing to the company’s strategic direction. The current CEO is James O'Mara.Neurogastrx, Inc. specializes in the discovery and development of innovative biopharmaceutical therapies aimed at addressing gastrointestinal disorders affecting the enteric nervous system. Their core products target critical health issues such as nausea and vomiting associated with GLP-1 agonists and gastroparesis, improving patient outcomes by effectively managing symptoms that significantly impact quality of life. The company aims to serve various clients, including healthcare providers and patients, and focuses on expanding access to its products across the US and potential international markets.Neurogastrx generates revenue through the commercialization of its specialized products targeting gastrointestinal disorders. The company operates primarily through partnerships with healthcare institutions that prescribe its therapies. Revenue is generated as these providers incorporate Neurogastrx’s products into their treatment protocols, supported by reimbursements from healthcare payers, ensuring steady demand for their innovative solutions.Following the USD 60.00 mn raised in Series B funding in August 2021 led by Vivo Capital, Neurogastrx, Inc. aims to advance its pipeline of gastrointestinal therapies for serious conditions. The funding will support the development of new products targeting additional GI disorders, with plans to expand into both domestic and international markets by 2023. The strategic focus includes enhancing product access and integrating new therapies into healthcare systems.

## Funding rounds

- Series B, Aug 26, 2021, $60M — OrbiMed Advisors, 5AM Ventures, Vivo Capital, Marshall Wace, VenBio, RTW Investments, Samsara BioCapital
- Series A, Jan 4, 2018, $45M — OrbiMed Advisors, 5AM Ventures, VenBio

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B